The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

In recent years, cancer genomics has provided new insights into genetic alterations and
signaling pathways involved in thyroid cancer. However, the picture of the molecular …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Diabetic retinopathy (DR) is a multifactorial neuro-microvascular disease, whose prevalence
ranges from 25% to 60% of subjects affected by diabetes mellitus, representing the main …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates
active iodide transport into the thyroid gland and into several extrathyroidal tissues. NIS …

Thyroid cancer is the most common malignancy of the endocrine system, encompassing
different entities with distinct histological features and clinical behavior. The diagnostic …

Glioblastoma multiforme (GBM) is the most common primary brain malignancy and is often
resistant to conventional treatments due to its extensive cellular heterogeneity. Thus, the …

The Insulin-like growth factor (IGF) axis is one of the best-established drivers of thyroid
transformation, as thyroid cancer cells overexpress both IGF ligands and their receptors …

The introduction of tyrosine kinase inhibitors (TKIs) directed against the catalytic activity of
the ABL tyrosine kinase has considerably improved the outcome of chronic myeloid …